Imunon Inc

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IMUNON reports Q1 loss, highlights promising cancer treatment progress

IMUNON shows progress in clinical trials with promising data; strong leadership and innovative technology driving growth. Financial challenges exist, but opportunities in expanding therapeutic applications and COVID vaccine development are promising.

Imunon Inc reports Q2 losses, optimistic on clinical advancements

Imunon Inc faces financial challenges but shows promise in clinical outcomes.
Strategic expense management and positive study results are key strengths.
Opportunities lie in partnerships, financing, and upcoming data releases.
Leadership's optimism reflects confidence in the company's progress.

Imunon Inc reports positive clinical results and secures funding for growth

Imunon Inc's Q3 2024 performance reflects promising clinical advancements and financial stability, with plans for a Phase III trial in the pipeline.
The company's strengths lie in strong clinical data, secured funding, strategic partnerships, and a focus on innovation in cancer therapies.
Challenges include managing increased expenses, navigating partnerships, competition, and regulatory hurdles, requiring careful strategic planning.
Opportunities abound in advancing to Phase III trials, exploring partnerships for the COVID-19 vaccine, and leveraging strategic hires for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable future manufacturing capability On track to initiate Phase 3 pivotal trial of IMNN-001 in first quarter of 2025 LAWRENCEVILLE, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the positive outcome of a Type C Chemistry, Manufacturing, and Controls (CMC) meeting with the U.S. Food and Drug Administration (FDA) regarding production of IMNN-001 for the treatment of women with newly diagnosed advanced ovarian cancer.

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT) population of women newly diagnosed with advanced ovarian cancer

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

FDA Project Team supports the company's proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and primary endpoint

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

Imunon, Inc. (NASDAQ:IMNN ) Q3 2024 Earnings Conference Call November 7, 2024 11:00 AM ET Company Participants Kim Golodetz - Alliance Advisors IR Stacy Lindborg - President & Chief Executive Officer David Gaiero - Interim Chief Financial Officer Michael Tardugno - Executive Chairman Conference Call Participants David Bautz - Zacks Kemp Dolliver - Brookline Capital Markets James Molloy - Alliance Global Partners Operator Hello everyone. Good morning.

Imunon, Inc. (IMNN) Q3 2024 Earnings Call Transcript

IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

Conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J.

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

LAWRENCEVILLE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, November 7, 2024 to discuss financial results for the third quarter ended September 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens for the development of next-generation vaccines.

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptance Company also announces FDA End-of-Phase 2 in-person meeting to discuss Phase 3 trial of IMNN-001 Phase 3 trial is expected to begin in Q1 2025 LAWRENCEVILLE, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the acceptance of a late-breaking presentation featuring new clinical data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational therapy for the treatment of advanced ovarian cancer, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held November 6-10, 2024, in Houston, Texas and virtually.

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

LAWRENCEVILLE, N.J., Oct. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) (the “Company”), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options to purchase a total of 60,000 shares of the Company's common stock to one individual hired by Imunon during the fourth quarter of 2024 and (ii) inducement stock options to purchase a total of 50,000 shares of common stock to Susan Eylward, hired by Imunon as General Counsel and Secretary effective October 7, 2024 (collectively, the “Inducement Option Grants”). The Inducement Option Grants were approved in accordance with Nasdaq Listing Rule 5635(c)(4) and were made on October 7, 2024, as a material inducement to each employee's entry into employment with the Company.

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

September 18 th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline

UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

R&D Discussion in New York City to Review IL-12's Potential to Treat Ovarian Cancer Program Features Ovarian Cancer Thought Leaders, OVATION 2 Study Investigators, and Oncology Experts LAWRENCEVILLE, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, invites investors to mark their calendars for its R&D Day event to be held at the Harvard Club in New York City on September 18th from 10:00 a.m.

IMUNON to Host R&D Day on September 18th

Imunon, Inc. (NASDAQ:IMNN ) Q2 2024 Results Conference Call August 14, 2024 11:00 AM ET Company Participants Kim Golodetz - IR Michael Tardugno - Executive Chairman Stacy Lindborg - President and CEO David Gaiero - Interim CFO Conference Call Participants Emily Bodnar - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets David Bautz - Zacks James Molloy - Alliance Global Partners Operator Good morning, everyone.

Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J.

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

LAWRENCEVILLE, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc . (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Wednesday, August 14, 2024 to discuss financial results for the second quarter ended June 30, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens for the development of next-generation vaccines.

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

IMUNON Inc IMNN stock is surging on Tuesday, with a strong session volume of 117.8 million as per data from Benzinga Pro.

Nano-Cap IMUNON's Lead Candidate Shows Overall Survival Of Around 11 Months In Untreated Ovarian Cancer Patients

Shares of Imunon Inc. skyrocketed on massive volume Tuesday, after the biotechnology company announced positive survival data from a trial of its ovarian cancer treatment, IMNN-001.

Imunon's stock rockets after ovarian cancer treatment's positive trial results

Imunon (NASDAQ: IMNN ) stock is rocketing higher on Tuesday as the clinical-stage company releases data from a Phase 2 clinical trial of IMNN-001. This is the company's treatment candidate for patients with advanced ovarian cancer.

Why Is Imunon (IMNN) Stock Up 259% Today?

Phase 2 OVATION 2 Study of IMNN-001 a dministered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74 in overall survival (OS) in the intent-to-treat patient population compared with the standard-of-care control arm OS was extended by 15.7 months in patients receiving three or more doses of IMNN-001 in the 17-dose protocol Patients also receiving maintenance PARP inhibitor therapy demonstrated an OS hazard ratio of 0.41 in the IMNN-001 trial arm with median OS not yet reached at the time of data lock Robust and durable benefit of IMNN-001 observed in OS supported by a three-month improvement in the primary endpoint of progression-free survival (PFS) IMUNON expects to initiate a registrational study in Q1 2025 Conference call begins today at 8:30 a.m. Eastern time LAWRENCEVILLE, N.J.

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001

Results to be announced at 8:00 a.m. Eastern time, conference call to begin at 8:30 a.m.

IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment Expects topline results by the end of July LAWRENCEVILLE, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in advanced development of its non-viral DNA-mediated immunotherapy, announces database lock for its Phase 2 OVATION 2 Study evaluating the safety and efficacy of IMNN-001 in patients with advanced ovarian cancer.

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapy and evaluating an adaptation of the platform's potential as a next-generation vaccine, announces that the first participants have been treated in the IMNN-101 Phase 1 clinical trial.

First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial

LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc.  (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin®) and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago from May 31st to June 4th.

Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting

Imunon, Inc. (NASDAQ:IMNN ) Q1 2024 Earnings Conference Call May 13, 2024 11:00 AM ET Company Participants Kim Golodetz - Investor Relations, LHA Michael Tardugno - Executive Chairman Stacy Lindborg - Chief Executive and President Kursheed Anwer - Chief Science Officer Sebastien Hazard - Chief Medical Officer Jeff Church - Chief Financial Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets James Molloy - Alliance Global Partners Operator Good morning.

Imunon, Inc. (IMNN) Q1 2024 Earnings Call Transcript

Proof-of-concept study for Imunon's first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment

News for Imunon Inc Stock (IMNN)